Eventide Asset Management
40
90M
29
2.50
4
0.28
16
- Areas of investment
Summary
The company was established in North America in United States. The main office of represented VC is situated in the Omaha.
We also calculated 3 valuable employees in our database.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Eventide Asset Management, startups are often financed by Third Rock Ventures, Wellcome Trust, The Column Group. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, EcoR1 Capital, TPG Biotech. In the next rounds fund is usually obtained by Zealand Pharma, TPG, Sofinnova Investments.
The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Eventide Asset Management performs on 15 percentage points more the average number of lead investments. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations.
We can highlight the next thriving fund investment areas, such as Medical Device, Health Diagnostics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Beta Bionics, Magenta Therapeutics, Karuna Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Investments analytics
Analytics
- Total investments
- 40
- Lead investments
- 4
- Exits
- 16
- Rounds per year
- 2.50
- Follow on index
- 0.28
- Investments by industry
- Biotechnology (37)
- Health Care (20)
- Therapeutics (18)
- Medical (13)
- Life Science (11) Show 9 more
- Investments by region
-
- United States (37)
- Switzerland (2)
- United Kingdom (1)
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 2
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 664M
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
- Avg. multiplicator
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Kojin Therapeutics | 09 Jun 2021 | Biotechnology, Medical, Life Science, Biopharma | Early Stage Venture | 60M | United States, Massachusetts, Cambridge |
| Sudo Biosciences | 13 Feb 2024 | Biopharma | Early Stage Venture | 30M | United States, Menlo Park, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.